Trial Profile
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Dec 2023
Price :
$35
*
At a glance
- Drugs Canakinumab (Primary)
- Indications Cardiovascular disorders
- Focus Proof of concept; Registrational; Therapeutic Use
- Acronyms CANTOS; CANTOS sub-study 1; CANTOS sub-study 2
- Sponsors Novartis; Novartis Pharmaceuticals
- 13 Nov 2023 Results validating associations between SUA and CV risk in a large cohort with chronic CAD and determining whether these associations were altered by IL-1b blockade or baseline renal function, presented at the American Heart Association Scientific Sessions 2023
- 15 Jun 2023 Results assessing Impact of Clonal Hematopoiesis and Canakinumab on Non-Hematological Malignancy presented at the 28th Congress of the European Haematology Association
- 09 Aug 2022 Results published in the European Heart Journal